Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Yearbook of Pediatrics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YPED.2011.06.087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 1 Parker et al Mitoxantrone improves outcome of children with first relapse of acute lymphoblastic leukaemia – results of the randomised

  2010cited by this paper

• Chronic parotitis and sialocele: An unusual cause of persistent facial swelling in a patient with relapsed leukemia

  2023cites this paper
• Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

  2023cites this paper
• Can CD34+CD38− lymphoblasts, as likely leukemia stem cells, be a prognostic factor in B-cell precursor acute lymphoblastic leukemia in children?

  2023cites this paper
• A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore

  2023cites this paper
• Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse

  2023cites this paper
• Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)

  2022cites this paper
• Acute lymphoblastic leukemia

  2022cites this paper
• Successful hematopoietic stem cell transplantation for two patients with relapse of intrachromosomal amplification of chromosome 21-positive B-cell precursor acute lymphoblastic leukemia

  2022cites this paper
• The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis

  2022cites this paper
• The prognostic effect on childhood acute lymphoblastic leukemia of CD34+CD38− expressed in leukemia cells

  2022cites this paper
• Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study

  2021cites this paper
• Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin

  2021cites this paper
• Isolated central nervous system leukemiarelapse presenting as Guillain-Barré-like syndrome: A case report

  2020cites this paper
• Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Pediatric Acute Lymphoblastic Leukemia, Version 2.2020

  2019cites this paper
• Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003

  2018cites this paper
• 1 Panel-based Next-generation Sequencing Identifies Prognostic and Actionable Genes in Childhood 1 Acute Lymphoblastic Leukemia and is Suitable for Clinical Sequencing 2 3

  2018cites this paper
• A Case Report on Pediatric Relapsed Acute Lymphoblastic Leukemia Patient with a novel t (1;7) (q32; p22) translocation

  2018cites this paper
• Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers

  2018cites this paper
• The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.

  2017influential citation
• Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study

  2017cites this paper
• The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood

  2017cites this paper
• A phase 1 trial of temsirolimus and intensive re‐induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)

  2017cites this paper
• Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia

  2016cites this paper
• CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response

  2016cites this paper
• Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience

  2015cites this paper
• Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia.

  2014cites this paper
• Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

  2014cites this paper
• Anti-Cancer (Novel Agents): A Review

  2014cites this paper
• T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia

  2014cites this paper
• Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

  2014cites this paper
• REVIEW Children's Oncology Group's 2013 Blueprint for Research: Acute Lymphoblastic Leukemia

  2013cites this paper
• Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

  2013cites this paper
• Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia

  2013cites this paper
• Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion

  2013cites this paper
• Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient.

  2012cites this paper
• Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia

  2011cites this paper
• Comment on: Severe toxicity and poor ef fi cacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial

  year unknowncites this paper